Renal Function in Glycogen Storage Disease Type I, Natural Course, and Renopreservative Effects of ACE Inhibition

被引:31
作者
Martens, Danielle H. J. [1 ]
Rake, Jan Peter [2 ]
Navis, Gerjan [3 ]
Fidler, Vaclav [4 ]
van Dael, Catharina M. L. [5 ]
Smit, G. Peter A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, NL-9700 RB Groningen, Netherlands
[2] Martini Hosp Groningen, Dept Pediat, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Nephrol, NL-9700 RB Groningen, Netherlands
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 4卷 / 11期
关键词
DIABETIC-NEPHROPATHY; BLOOD-PRESSURE; ESGSD-I; MANAGEMENT; CHILDREN;
D O I
10.2215/CJN.00050109
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Renal failure is a major complication in glycogen storage disease type I (GSD I). We studied the natural course of renal function in GSD I patients. We studied differences between patients in optimal and nonoptimal metabolic control and possible renoprotective effects of angiotensin converting enzyme inhibition. Design, setting, participants, & measurements: Thirty-nine GSD I patients that visited our clinic were studied. GFR and effective renal plasma flow (ERPF) were measured by means of I-125 iothalamate and I-131 hippuran clearance and corrected for body surface area. Microalbuminuria was defined as >2.5 mg albumin/mmol creatinine and proteinuria as >0.2 g protein per liter. Optimal metabolic control was present when blood glucoses were >3.5 mmol/L, urine lactate/creatinine ratios <0.06 mmol/mmol, triglycerides <6.0 mmol/L, and uric acid concentrations <450 mu mol/L. Results: Quadratic regression analysis showed a biphasic pattern in the course of GFR and ERPF related to age. Microalbuminuria was observed significantly less frequently in the patients with optimal metabolic control compared with the patients with nortoptimal metabolic control. A significant decrease in GFR was observed after starting ACE inhibition. Conclusions: This study describes a biphasic pattern of the natural course of GFR and ERPF in GSD I patients, followed by the development of microalbuminuria and proteinuria. Optimal metabolic control has a renoprotective effect on the development of microalbuminuria and proteinuria in GSD I patients. Treatment with ACE inhibitors significantly decreases the GFR especially in GSD I patients with glomerular hyperfiltration. Clin J Ant Soc Nephrol 4: 1741-1746, 2009. doi: 10.2215/CJN.00050109
引用
收藏
页码:1741 / 1746
页数:6
相关论文
共 40 条
  • [31] Early ACE-I intervention in microalbuminuric patients with type 1 diabetes: effects on albumin excretion, 24 h ambulatory blood pressure and renal function
    Poulsen, PL
    Ebbehoj, E
    Nosadini, R
    Fioretto, P
    Deferrari, G
    Crepaldi, G
    Mogensen, CE
    DIABETES & METABOLISM, 2001, 27 (02): : 123 - 128
  • [32] Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers
    Chiu, Li-Ya
    Kishnani, Priya S.
    Chuang, Tzu-Po
    Tang, Cheng-Yang
    Liu, Cheng-Yuan
    Bali, Deeksha
    Koeberl, Dwight
    Austin, Stephanie
    Boyette, Keri
    Weinstein, David A.
    Murphy, Elaine
    Yao, Adam
    Chen, Yuan-Tsong
    Li, Ling-Hui
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (08) : 1274 - 1284
  • [33] Over 11 years of stable renal function after remission of nephrotic-range proteinuria in type I diabetics treated with an ACE inhibitor
    McGregor, D
    Bailey, RR
    NEPHRON, 1997, 76 (03): : 270 - 275
  • [34] A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study
    Bhattacharya, Kaustuv
    Mundy, Helen
    Lilburn, Maggie F.
    Champion, Michael P.
    Morley, David W.
    Maillot, Francois
    ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [35] Safety and Efficacy of DTX401, an AAV8-Mediated Liver-Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a (GSDIa)
    Weinstein, David A.
    Derks, Terry G.
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Couce, Maria-Luz
    Mitchell, John J.
    Riba-Wolman, Rebecca
    Mount, Malaya
    Sallago, Julieta Bonvin
    Ross, Katalin M.
    van Der Klauw, Melanie M.
    de Boer, Foekje
    van Der Schaaf, Caroline
    Saavedra, Heather
    Martinez-Olmos, Miguel
    Atanga, Elvis
    Hosseini, Asad
    Mitragotri, Deepali
    Crombez, Eric
    JOURNAL OF INHERITED METABOLIC DISEASE, 2025, 48 (02)
  • [36] Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study
    Furusawa, Yoshihiko
    Mori-Yoshimura, Madoka
    Yamamoto, Toshiyuki
    Sakamoto, Chikako
    Wakita, Mizuki
    Kobayashi, Yoko
    Fukumoto, Yutaka
    Oya, Yasushi
    Fukuda, Tokiko
    Sugie, Hideo
    Hayashi, Yukiko K.
    Nishino, Ichizo
    Nonaka, Ikuya
    Murata, Miho
    JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 (02) : 301 - 310
  • [37] Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
    Xu, Lubin
    Li, Yang
    Lang, Jiaxin
    Xia, Peng
    Zhao, Xinyu
    Wang, Li
    Yu, Yang
    Chen, Limeng
    PEERJ, 2017, 5 : e3405
  • [38] Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function"
    Pugliese, Giuseppe
    Penno, Giuseppe
    Natali, Andrea
    Barutta, Federica
    Di Paolo, Salvatore
    Reboldi, Gianpaolo
    Gesualdo, Loreto
    De Nicola, Luca
    JOURNAL OF NEPHROLOGY, 2020, 33 (01) : 9 - 35
  • [39] Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”
    Giuseppe Pugliese
    Giuseppe Penno
    Andrea Natali
    Federica Barutta
    Salvatore Di Paolo
    Gianpaolo Reboldi
    Loreto Gesualdo
    Luca De Nicola
    Journal of Nephrology, 2020, 33 : 9 - 35
  • [40] Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function"
    Pugliese, Giuseppe
    Penno, Giuseppe
    Natali, Andrea
    Barutta, Federica
    Di Paolo, Salvatore
    Reboldi, Gianpaolo
    Gesualdo, Loreto
    De Nicola, Luca
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2019, 29 (11) : 1127 - 1150